Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib

Eric L. Simpson, Andreas Wollenberg, Robert Bissonnette, Jonathan I. Silverberg, Jocelyne Papacharalambous, Linda Zhu, Weidong Zhang, Jean S. Beebe, Michael Vincent, Elena Peeva, Andrew G. Bushmakin, Joseph C. Cappelleri, Linda Chen, Vanja Sikirica, Jason Xenakis

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) is inadequately controlled with current treatments for many patients. Abrocitinib is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of AD. OBJECTIVE: The aim of the study was to evaluate patient-reported outcomes in a phase 2b study of abrocitinib in adults with moderate-to-severe AD inadequately controlled by topical therapy (NCT02780167). METHODS: Patients (N = 267) were randomly assigned 1:1:1:1:1 to 12-week, once-daily abrocitinib (200, 100, 30, 10 mg) or placebo. Patient-reported outcomes included pruritus numeric rating scale (average), Patient Global Assessment, Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale (HADS). RESULTS: Abrocitinib 200 or 100 mg resulted in significantly greater improvements from baseline versus placebo in peak pruritus numeric rating scale (by days 2 and 3, respectively), Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and HADS (200 mg only, by week 1 or 2), and proportions of the patients with Patient Global Assessment clear/almost clear with 2-point or greater improvement (by weeks 1 and 4, respectively) that continued through week 12 (except HADS). CONCLUSIONS: Abrocitinib treatment resulted in rapid (2 days to 2 weeks) and persistent improvements in AD symptoms and impacts in moderate-to-severe disease.

Original languageEnglish (US)
Pages (from-to)S53-S61
JournalDermatitis : contact, atopic, occupational, drug
Volume32
Issue number1
DOIs
StatePublished - Oct 1 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Dermatology

Fingerprint

Dive into the research topics of 'Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib'. Together they form a unique fingerprint.

Cite this